Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 523

1.

High-Frequency Biomarker Measurements of Troponin, NT-proBNP, and C-Reactive Protein for Prediction of New Coronary Events After Acute Coronary Syndrome.

Oemrawsingh RM, Akkerhuis KM, de Mulder M, Umans VA, Kietselaer B, Schotborgh C, Ronner E, Lenderink T, Liem A, Haitsma D, van der Harst P, Asselbergs FW, Maas A, Oude Ophuis AJ, Ilmer B, Dijkgraaf R, de Winter RJ, Kie The SH, Wardeh AJ, Hermans W, Cramer E, van Schaik RH, Hoefer IE, Doevendans PA, Simoons ML, Boersma E; BIOMArCS Investigators.

Circulation. 2019 Jan 2;139(1):134-136. doi: 10.1161/CIRCULATIONAHA.118.036349. No abstract available.

PMID:
30592652
2.

The ESC Publications Ethics Committee: Report from the first 5 years' experience of the European Society of Cardiology (ESC) journals family ethics committee.

all Committee Members, Simoons ML.

Eur Heart J. 2018 Jul 14;39(27):2518-2521. doi: 10.1093/eurheartj/ehy323. No abstract available.

PMID:
30010827
3.

The Treatment Effect of an ACE-Inhibitor Based Regimen with Perindopril in Relation to Beta-Blocker use in 29,463 Patients with Vascular Disease: a Combined Analysis of Individual Data of ADVANCE, EUROPA and PROGRESS Trials.

Brugts JJ, Bertrand M, Remme W, Ferrari R, Fox K, MacMahon S, Chalmers J, Simoons ML, Boersma E.

Cardiovasc Drugs Ther. 2017 Aug;31(4):391-400. doi: 10.1007/s10557-017-6747-9.

4.

Cohort profile of BIOMArCS: the BIOMarker study to identify the Acute risk of a Coronary Syndrome-a prospective multicentre biomarker study conducted in the Netherlands.

Oemrawsingh RM, Akkerhuis KM, Umans VA, Kietselaer B, Schotborgh C, Ronner E, Lenderink T, Liem A, Haitsma D, van der Harst P, Asselbergs FW, Maas A, Oude Ophuis AJ, Ilmer B, Dijkgraaf R, de Winter RJ, The SH, Wardeh AJ, Hermans W, Cramer E, van Schaik RH, Hoefer IE, Doevendans PA, Simoons ML, Boersma E.

BMJ Open. 2016 Dec 23;6(12):e012929. doi: 10.1136/bmjopen-2016-012929.

5.

Individualized Angiotensin-Converting Enzyme (ACE)-Inhibitor Therapy in Stable Coronary Artery Disease Based on Clinical and Pharmacogenetic Determinants: The PERindopril GENEtic (PERGENE) Risk Model.

Oemrawsingh RM, Akkerhuis KM, Van Vark LC, Redekop WK, Rudez G, Remme WJ, Bertrand ME, Fox KM, Ferrari R, Danser AH, de Maat M, Simoons ML, Brugts JJ, Boersma E; PERGENE investigators.

J Am Heart Assoc. 2016 Mar 28;5(3):e002688. doi: 10.1161/JAHA.115.002688.

6.

How can the European Society of Cardiology ensure compliance with ethical standards?

Simoons ML, Bassand JP, Bax J, Bertrand M, Breithardt G, Ferrari R, Fox K, Hugenholtz P, Komajda M, Pinto F, Rydén L, Tendera M, Vardas P.

Eur Heart J. 2016 Mar 1;37(9):741-4. doi: 10.1093/eurheartj/ehv651. Epub 2015 Dec 18. No abstract available.

PMID:
26685144
7.
8.

Intensive LDL lowering therapy for prevention of recurrent cardiovascular events: a word of caution.

Simoons ML, Deckers JW.

Eur Heart J. 2016 Feb 7;37(6):520-3. doi: 10.1093/eurheartj/ehv616. Epub 2015 Nov 3. No abstract available.

PMID:
26537621
9.

[LDL cholesterol lowering therapy: no target value but personalised treatment].

Simoons ML, Deckers JW.

Ned Tijdschr Geneeskd. 2015;159:A8770. Dutch.

PMID:
25923500
10.

Prediction of absolute risk reduction of cardiovascular events with perindopril for individual patients with stable coronary artery disease - results from EUROPA.

van der Leeuw J, Oemrawsingh RM, van der Graaf Y, Brugts JJ, Deckers JW, Bertrand M, Fox K, Ferrari R, Remme WJ, Simoons ML, Boersma E, Visseren FL.

Int J Cardiol. 2015 Mar 1;182:194-9. doi: 10.1016/j.ijcard.2014.12.046. Epub 2014 Dec 23.

11.

The incidence and clinical predictors of ACE-inhibitor induced dry cough by perindopril in 27,492 patients with vascular disease.

Brugts JJ, Arima H, Remme W, Bertrand M, Ferrari R, Fox K, DiNicolantonio J, MacMahon S, Chalmers J, Zijlstra F, Caliskan K, Simoons ML, Mourad JJ, Boersma E, Akkerhuis KM.

Int J Cardiol. 2014 Oct 20;176(3):718-23. doi: 10.1016/j.ijcard.2014.07.108. Epub 2014 Aug 1.

PMID:
25189490
12.

Conventional hemodynamic resuscitation may fail to optimize tissue perfusion: an observational study on the effects of dobutamine, enoximone, and norepinephrine in patients with acute myocardial infarction complicated by cardiogenic shock.

den Uil CA, Lagrand WK, van der Ent M, Nieman K, Struijs A, Jewbali LS, Constantinescu AA, Spronk PE, Simoons ML.

PLoS One. 2014 Aug 1;9(8):e103978. doi: 10.1371/journal.pone.0103978. eCollection 2014.

13.

Identifying genetic risk variants for coronary heart disease in familial hypercholesterolemia: an extreme genetics approach.

Versmissen J, Oosterveer DM, Yazdanpanah M, Dehghan A, Hólm H, Erdman J, Aulchenko YS, Thorleifsson G, Schunkert H, Huijgen R, Vongpromek R, Uitterlinden AG, Defesche JC, van Duijn CM, Mulder M, Dadd T, Karlsson HD, Ordovas J, Kindt I, Jarman A, Hofman A, van Vark-van der Zee L, Blommesteijn-Touw AC, Kwekkeboom J, Liem AH, van der Ouderaa FJ, Calandra S, Bertolini S, Averna M, Langslet G, Ose L, Ros E, Almagro F, de Leeuw PW, Civeira F, Masana L, Pintó X, Simoons ML, Schinkel AF, Green MR, Zwinderman AH, Johnson KJ, Schaefer A, Neil A, Witteman JC, Humphries SE, Kastelein JJ, Sijbrands EJ.

Eur J Hum Genet. 2015 Mar;23(3):381-7. doi: 10.1038/ejhg.2014.101. Epub 2014 Jun 11.

14.

Risk stratification for sudden cardiac death: current status and challenges for the future.

Wellens HJ, Schwartz PJ, Lindemans FW, Buxton AE, Goldberger JJ, Hohnloser SH, Huikuri HV, Kääb S, La Rovere MT, Malik M, Myerburg RJ, Simoons ML, Swedberg K, Tijssen J, Voors AA, Wilde AA.

Eur Heart J. 2014 Jul 1;35(25):1642-51. doi: 10.1093/eurheartj/ehu176. Epub 2014 May 5.

15.

[Abandon LDL cholesterol target levels].

Deckers JW, Simoons ML.

Ned Tijdschr Geneeskd. 2014;158:A7385. Dutch.

PMID:
24618241
16.

The grey zone of truth.

Simoons ML.

Eur Heart J. 2014 Sep 21;35(36):2445-7. doi: 10.1093/eurheartj/eht498. Epub 2013 Dec 17. No abstract available.

PMID:
24347318
17.

Genetic variation and gender determine bradykinin type 1 receptor responses in human tissue: implications for the ACE-inhibitor-induced effects in patients with coronary artery disease.

Wu H, Roks AJ, Leijten FP, Garrelds IM, Musterd-Bhaggoe UM, van den Bogaerdt AJ, de Maat MP, Simoons ML, Danser AH, Oeseburg H.

Clin Sci (Lond). 2014 Mar;126(6):441-9. doi: 10.1042/CS20130204.

PMID:
24117346
18.

Clinical and prognostic implications of circulating pentraxin 3 levels in non ST-elevation acute coronary syndrome.

Eggers KM, Armstrong PW, Califf RM, Johnston N, Simoons ML, Venge P, James SK.

Clin Biochem. 2013 Nov;46(16-17):1655-9. doi: 10.1016/j.clinbiochem.2013.08.014. Epub 2013 Sep 5.

PMID:
24012697
19.

2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology.

Task Force Members, Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, Bugiardini R, Crea F, Cuisset T, Di Mario C, Ferreira JR, Gersh BJ, Gitt AK, Hulot JS, Marx N, Opie LH, Pfisterer M, Prescott E, Ruschitzka F, Sabaté M, Senior R, Taggart DP, van der Wall EE, Vrints CJ; ESC Committee for Practice Guidelines, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S; Document Reviewers, Knuuti J, Valgimigli M, Bueno H, Claeys MJ, Donner-Banzhoff N, Erol C, Frank H, Funck-Brentano C, Gaemperli O, Gonzalez-Juanatey JR, Hamilos M, Hasdai D, Husted S, James SK, Kervinen K, Kolh P, Kristensen SD, Lancellotti P, Maggioni AP, Piepoli MF, Pries AR, Romeo F, Rydén L, Simoons ML, Sirnes PA, Steg PG, Timmis A, Wijns W, Windecker S, Yildirir A, Zamorano JL.

Eur Heart J. 2013 Oct;34(38):2949-3003. doi: 10.1093/eurheartj/eht296. Epub 2013 Aug 30. No abstract available. Erratum in: Eur Heart J. 2014 Sep 1;35(33):2260-1.

PMID:
23996286
20.

Dabigatran versus warfarin in patients with mechanical heart valves.

Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ, Blatchford J, Devenny K, Friedman J, Guiver K, Harper R, Khder Y, Lobmeyer MT, Maas H, Voigt JU, Simoons ML, Van de Werf F; RE-ALIGN Investigators.

N Engl J Med. 2013 Sep 26;369(13):1206-14. doi: 10.1056/NEJMoa1300615. Epub 2013 Aug 31.

21.

The European heart journal launches ethics review board.

Luscher TF, Simoons ML.

Eur Heart J. 2013 Jul;34(28):2107-13. doi: 10.1093/eurheartj/eht231. No abstract available.

PMID:
23872325
22.

Costs and benefits of treatment of myocardial infarction.

Simoons ML.

Neth Heart J. 2013 May;21(5):228-9. doi: 10.1007/s12471-013-0410-2. No abstract available.

23.

Development and validation of a cardiovascular risk assessment model in patients with established coronary artery disease.

Battes L, Barendse R, Steyerberg EW, Simoons ML, Deckers JW, Nieboer D, Bertrand M, Ferrari R, Remme WJ, Fox K, Takkenberg JJ, Boersma E, Kardys I.

Am J Cardiol. 2013 Jul 1;112(1):27-33. doi: 10.1016/j.amjcard.2013.02.049. Epub 2013 Apr 1.

PMID:
23558041
24.

Antithrombotic outcome trials in acute coronary syndromes: seeking the optimal balance between safety and efficacy.

Verheugt FW, Clemmensen P, Mehran R, Agewall S, Pocock SJ, Goldstein S, Torp-Pedersen C, Simoons ML, Borer JS, Khder YM, Burton P, Deliargyris E, McMurray JJ, Berkowitz SD, Stough WG, Zannad F.

Eur Heart J. 2013 Jun;34(22):1621-9. doi: 10.1093/eurheartj/eht013. Epub 2013 Feb 4. No abstract available.

PMID:
23382466
25.

Third universal definition of myocardial infarction.

Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD; Writing Group on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction.

Glob Heart. 2012 Dec;7(4):275-95. doi: 10.1016/j.gheart.2012.08.001. Epub 2012 Sep 26. No abstract available.

26.

UPDATE programmes of the European Society of Cardiology.

Simoons ML, Zijlstra F.

Eur Heart J. 2012 Sep;33(18):2239-40. No abstract available.

PMID:
23145444
27.

Genetic influences of angiotensin-converting enzyme inhibitor response: an opportunity for personalizing therapy?

Brugts JJ, Simoons ML.

Expert Rev Cardiovasc Ther. 2012 Aug;10(8):1001-9. doi: 10.1586/erc.12.83. Review.

PMID:
23030290
28.

Third universal definition of myocardial infarction.

Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD; Joint ESC/ACCF/AHA/WHF Task Force for Universal Definition of Myocardial Infarction; Authors/Task Force Members Chairpersons, Thygesen K, Alpert JS, White HD; Biomarker Subcommittee, Jaffe AS, Katus HA, Apple FS, Lindahl B, Morrow DA; ECG Subcommittee, Chaitman BR, Clemmensen PM, Johanson P, Hod H; Imaging Subcommittee, Underwood R, Bax JJ, Bonow JJ, Pinto F, Gibbons RJ; Classification Subcommittee, Fox KA, Atar D, Newby LK, Galvani M, Hamm CW; Intervention Subcommittee, Uretsky BF, Steg PG, Wijns W, Bassand JP, Menasche P, Ravkilde J; Trials & Registries Subcommittee, Ohman EM, Antman EM, Wallentin LC, Armstrong PW, Simoons ML; Trials & Registries Subcommittee, Januzzi JL, Nieminen MS, Gheorghiade M, Filippatos G; Trials & Registries Subcommittee, Luepker RV, Fortmann SP, Rosamond WD, Levy D, Wood D; Trials & Registries Subcommittee, Smith SC, Hu D, Lopez-Sendon JL, Robertson RM, Weaver D, Tendera M, Bove AA, Parkhomenko AN, Vasilieva EJ, Mendis S; ESC Committee for Practice Guidelines (CPG), Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S; Document Reviewers, Morais J, Aguiar C, Almahmeed W, Arnar DO, Barili F, Bloch KD, Bolger AF, Botker HE, Bozkurt B, Bugiardini R, Cannon C, de Lemos J, Eberli FR, Escobar E, Hlatky M, James S, Kern KB, Moliterno DJ, Mueller C, Neskovic AN, Pieske BM, Schulman SP, Storey RF, Taubert KA, Vranckx P, Wagner DR.

J Am Coll Cardiol. 2012 Oct 16;60(16):1581-98. doi: 10.1016/j.jacc.2012.08.001. Epub 2012 Sep 5. No abstract available.

29.

Third universal definition of myocardial infarction.

Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD; Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction, Katus HA, Lindahl B, Morrow DA, Clemmensen PM, Johanson P, Hod H, Underwood R, Bax JJ, Bonow RO, Pinto F, Gibbons RJ, Fox KA, Atar D, Newby LK, Galvani M, Hamm CW, Uretsky BF, Steg PG, Wijns W, Bassand JP, Menasché P, Ravkilde J, Ohman EM, Antman EM, Wallentin LC, Armstrong PW, Simoons ML, Januzzi JL, Nieminen MS, Gheorghiade M, Filippatos G, Luepker RV, Fortmann SP, Rosamond WD, Levy D, Wood D, Smith SC, Hu D, Lopez-Sendon JL, Robertson RM, Weaver D, Tendera M, Bove AA, Parkhomenko AN, Vasilieva EJ, Mendis S.

Circulation. 2012 Oct 16;126(16):2020-35. doi: 10.1161/CIR.0b013e31826e1058. Epub 2012 Aug 24. No abstract available.

PMID:
22923432
30.

Third universal definition of myocardial infarction.

Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD; Task Force for the Universal Definition of Myocardial Infarction.

Nat Rev Cardiol. 2012 Nov;9(11):620-33. doi: 10.1038/nrcardio.2012.122. Epub 2012 Aug 25. Review. No abstract available.

PMID:
22922597
31.

Third universal definition of myocardial infarction.

Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD; Writing Group on the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction, Thygesen K, Alpert JS, White HD, Jaffe AS, Katus HA, Apple FS, Lindahl B, Morrow DA, Chaitman BA, Clemmensen PM, Johanson P, Hod H, Underwood R, Bax JJ, Bonow RO, Pinto F, Gibbons RJ, Fox KA, Atar D, Newby LK, Galvani M, Hamm CW, Uretsky BF, Steg PG, Wijns W, Bassand JP, Menasché P, Ravkilde J, Ohman EM, Antman EM, Wallentin LC, Armstrong PW, Simoons ML, Januzzi JL, Nieminen MS, Gheorghiade M, Filippatos G, Luepker RV, Fortmann SP, Rosamond WD, Levy D, Wood D, Smith SC, Hu D, Lopez-Sendon JL, Robertson RM, Weaver D, Tendera M, Bove AA, Parkhomenko AN, Vasilieva EJ, Mendis S; ESC Committee for Practice Guidelines (CPG).

Eur Heart J. 2012 Oct;33(20):2551-67. doi: 10.1093/eurheartj/ehs184. Epub 2012 Aug 24. No abstract available.

PMID:
22922414
32.

Frequency of asymptomatic disease among family members with noncompaction cardiomyopathy.

Caliskan K, Michels M, Geleijnse ML, van Domburg RT, van der Boon R, Balk AH, Simoons ML.

Am J Cardiol. 2012 Nov 15;110(10):1512-7. doi: 10.1016/j.amjcard.2012.07.009. Epub 2012 Aug 8.

PMID:
22883165
33.

The prevalence of early repolarization in patients with noncompaction cardiomyopathy presenting with malignant ventricular arrhythmias.

Caliskan K, Ujvari B, Bauernfeind T, Theuns DA, Van Domburg RT, Akca F, Jordaens L, Simoons ML, Szili-Torok T.

J Cardiovasc Electrophysiol. 2012 Sep;23(9):938-44. doi: 10.1111/j.1540-8167.2012.02325.x. Epub 2012 May 15.

PMID:
22587370
34.

No relationship between left ventricular radial wall motion and longitudinal velocity and the extent and severity of noncompaction cardiomyopathy.

Caliskan K, Soliman OI, Nemes A, van Domburg RT, Simoons ML, Geleijnse ML.

Cardiovasc Ultrasound. 2012 Mar 19;10:9. doi: 10.1186/1476-7120-10-9.

35.

The need for a benchmark of the practice of cardiology.

Simoons ML.

Neth Heart J. 2012 Mar;20(3):91-3. doi: 10.1007/s12471-012-0253-2. No abstract available.

36.

Trends in clinical trials of non-ST-segment elevation acute coronary syndromes over 15 years.

Chan MY, Sun JL, Newby LK, Lokhnygina Y, White HD, Moliterno DJ, Théroux P, Ohman EM, Simoons ML, Mahaffey KW, Pieper KS, Giugliano RP, Armstrong PW, Califf RM, Van de Werf F, Harrington RA.

Int J Cardiol. 2013 Jul 31;167(2):548-54. doi: 10.1016/j.ijcard.2012.01.065. Epub 2012 Feb 17. Review.

PMID:
22341697
37.

Changes in clinical profile, treatment, and mortality in patients hospitalised for acute myocardial infarction between 1985 and 2008.

Nauta ST, Deckers JW, Akkerhuis M, Lenzen M, Simoons ML, van Domburg RT.

PLoS One. 2011;6(11):e26917. doi: 10.1371/journal.pone.0026917. Epub 2011 Nov 2.

38.

Three life years gained after reperfusion therapy in acute myocardial infarction: 25-30 years after a randomized controlled trial.

Domburg RT, Hendriks JM, Kamp O, Smits P, Melle Mv, Schenkeveld L, Bax JJ, Simoons ML.

Eur J Prev Cardiol. 2012 Dec;19(6):1316-23. doi: 10.1177/1741826711428064. Epub 2011 Oct 19.

PMID:
22013152
39.

A systematic review on pharmacogenetics in cardiovascular disease: is it ready for clinical application?

Verschuren JJ, Trompet S, Wessels JA, Guchelaar HJ, de Maat MP, Simoons ML, Jukema JW.

Eur Heart J. 2012 Jan;33(2):165-75. doi: 10.1093/eurheartj/ehr239. Epub 2011 Jul 30. Review.

PMID:
21804109
40.
41.

The in vitro effect of the new antithrombotic drug candidate ALX-0081 on blood samples of patients undergoing percutaneous coronary intervention.

van Loon JE, de Jaegere PP, Ulrichts H, van Vliet HH, de Maat MP, de Groot PG, Simoons ML, Leebeek FW.

Thromb Haemost. 2011 Jul;106(1):165-71. doi: 10.1160/TH10-12-0804. Epub 2011 Jun 9.

PMID:
21655675
42.

Multimarker risk model containing troponin-T, interleukin 10, myeloperoxidase and placental growth factor predicts long-term cardiovascular risk after non-ST-segment elevation acute coronary syndrome.

Oemrawsingh RM, Lenderink T, Akkerhuis KM, Heeschen C, Baldus S, Fichtlscherer S, Hamm CW, Simoons ML, Boersma E; CAPTURE investigators.

Heart. 2011 Jul;97(13):1061-6. doi: 10.1136/hrt.2010.197392. Epub 2011 May 10.

PMID:
21558475
43.

A half ounce of prevention ...

Simoons ML.

Eur Heart J. 2011 Sep;32(17):2098-9. doi: 10.1093/eurheartj/ehr090. Epub 2011 Apr 26. No abstract available.

PMID:
21525026
44.

The chest pain patient dilemma and discussion for chest pain units.

Simoons ML.

Eur Heart J. 2011 Mar;32(6):655. No abstract available.

PMID:
21523939
45.

Encouraging survival rates in patients with acute myocardial infarction treated with an intra-aortic balloon pump.

Valk SD, Cheng JM, den Uil CA, Lagrand WK, van der Ent M, van de Sande M, van Domburg RT, Simoons ML.

Neth Heart J. 2011 Mar;19(3):112-118. Epub 2011 Jan 18.

46.

The role of insulin therapy and glucose normalisation in patients with acute coronary syndrome.

Lipton JA, Can A, Akoudad S, Simoons ML.

Neth Heart J. 2011 Feb;19(2):79-84. Epub 2011 Jan 18.

47.

Indications and outcome of implantable cardioverter-defibrillators for primary and secondary prophylaxis in patients with noncompaction cardiomyopathy.

Caliskan K, Szili-Torok T, Theuns DA, Kardos A, Geleijnse ML, Balk AH, van Domburg RT, Jordaens L, Simoons ML.

J Cardiovasc Electrophysiol. 2011 Aug;22(8):898-904. doi: 10.1111/j.1540-8167.2011.02015.x. Epub 2011 Feb 18.

PMID:
21332865
48.

Impact of an alerting clinical decision support system for glucose control on protocol compliance and glycemic control in the intensive cardiac care unit.

Lipton JA, Barendse RJ, Schinkel AF, Akkerhuis KM, Simoons ML, Sijbrands EJ.

Diabetes Technol Ther. 2011 Mar;13(3):343-9. doi: 10.1089/dia.2010.0100. Epub 2011 Feb 3.

PMID:
21291336
49.

A pharmacogenetic analysis of determinants of hypertension and blood pressure response to angiotensin-converting enzyme inhibitor therapy in patients with vascular disease and healthy individuals.

Brugts JJ, Isaacs A, de Maat MP, Boersma E, van Duijn CM, Akkerhuis KM, Uitterlinden AG, Witteman JC, Cambien F, Ceconi C, Remme W, Bertrand M, Ninomiya T, Harrap S, Chalmers J, Macmahon S, Fox K, Ferrari R, Simoons ML, Danser AJ.

J Hypertens. 2011 Mar;29(3):509-19. doi: 10.1097/HJH.0b013e328341d117.

PMID:
21157371
50.

Towards individualized preventive therapy.

Simoons ML, Sijbrands EJ, Nieman K.

Eur Heart J. 2010 Nov;31(21):2565-6a. No abstract available.

PMID:
21080526

Supplemental Content

Loading ...
Support Center